19.02.2013 Views

2006 proposed fee schedule - American Society of Clinical Oncology

2006 proposed fee schedule - American Society of Clinical Oncology

2006 proposed fee schedule - American Society of Clinical Oncology

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Drugs<br />

Second Quarter<br />

ASP +6<br />

Percent<br />

Vancomycin $3.19<br />

(3) Estimated Medicare Payments using 95 Percent <strong>of</strong> AWP<br />

In order to estimate AWP payments we used the first<br />

quarter 2005 AWP prices and updated them to the second<br />

129<br />

quarter by applying, for drugs other than EPO, an estimated<br />

AWP quarterly growth <strong>of</strong> approximately 0.74 percent (annual<br />

growth factor <strong>of</strong> 3 percent). This growth factor is based on<br />

historical trends <strong>of</strong> AWP pricing (for all drugs) for the<br />

year 1997-2003. We did not increase the payment rate for<br />

Epogen since payment was maintained at $10.00 per thousand<br />

units prior to MMA. (See Table 21.)<br />

TABLE 21<br />

Drugs<br />

AWP Rates for the Second<br />

Quarter <strong>of</strong> 2005<br />

Epogen $10.00*<br />

Calcitriol $1.40<br />

Doxercalciferol $3.11<br />

Iron_dextran $18.04<br />

Iron_sucrose $0.66<br />

Levocarnitine $36.75<br />

Paricalcitol $5.37<br />

Sodium_ferric_glut $8.23<br />

Alteplase, Recombinant $38.82<br />

Vancomycin $5.55<br />

*Statutory rate.<br />

(4) Dialysis Treatments<br />

We updated the number <strong>of</strong> dialysis treatments by the<br />

actuarial projected growth in the number <strong>of</strong> ESRD<br />

beneficiaries. Since Medicare covers a maximum <strong>of</strong> three<br />

treatments per week, utilization growth is limited, and,

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!